Feasibility test to treat PhALL patients with autoPBSCT and TKI maintenance therapy

Feasibility test to treat PhALL patients with autoPBSCT and TKI maintenance therapy - autoPBSCT and TKI treatment for PhALL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012648

Enrollment

Registered

2013-12-21

Start date

2013-06-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ph1-positive acute lymphoblastc leukemia

Interventions

Treat PhALL patients with both autoPBSCT and tyrosine kinase inhibitor.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. de novo PhALL who achieved molecular CR 2. 50 to 70 yeas old 3. ECOG 0,1 4. Patients who have ability to undergo autoPBSCT 5. Not applicable alloSCT 6. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients who have other active malignant disease 2. Patients who have uncontrolled severe complications 3. Patients who have uncontrolled psychological disease 4. Patients who have dementia 5. Patients who have difficulties to receive scheduled treatment.

Design outcomes

Primary

Measure	Time frame
Survival, TRM and non-hematological AE at day 100	—

Countries

Japan

Contacts

Public ContactTakeshi Kondo

Hokkaido University Graduate School of Medicine Dept. of Hematology

t-kondoh@med.hokudai.ac.jp011-706-7214

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026